Ignite Creation Date:
2025-12-25 @ 4:02 AM
Ignite Modification Date:
2026-01-03 @ 12:58 AM
Study NCT ID:
NCT01376102
Status:
COMPLETED
Last Update Posted:
2014-06-16
First Post:
2011-06-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)
Sponsor:
GlaxoSmithKline
Organization:
Study Overview
Official Title:
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety of BONVIVA(Ibandronate) Injection Administered in Korean Patients According to the Prescribing Information
Status:
COMPLETED
Status Verified Date:
2014-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BONINJPMS
Brief Summary:
This is an open label, multi-centre, non-interventional post-marketing surveillance
Detailed Description:
This is an open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of Ibandronate injection administered in postmenopausal osteoporosis patients according to the prescribing information
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: